Abstract 5353
Background
9-ING-41 is a first-in-class, intravenously (IV) administered, small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity in a broad spectrum of malignancies, both as a single agent and in combination with cytotoxic agents. GSK-3β is a serine/threonine kinase important in tumor progression and modulation of oncogenes, cell cycle regulators and mediators of epithelial-mesenchymal transition. Aberrant overexpression of GSK-3β is associated with advanced stage and aggressive tumor growth as well as chemotherapy resistance.
Trial design
This Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41 as a single agent and in combination with cytotoxic agents, in patients with refractory cancers. Treatment consists of twice-weekly IV infusion of 9-ING-41 as a single agent (21-day-cycle) or combined with chemotherapeutic agents including gemcitabine, doxorubicin, lomustine, carboplatin, nab-paclitaxel, or paclitaxel. Study parts 1 and 2 will evaluate the safety and tolerability, describe any dose-limiting toxicity (DLT), determine the maximum tolerated dose (MTD) and the recommended Phase 2 study dose (RP2D) for 9-ING-41 as monotherapy (Part 1) and in combination with chemotherapies (Part 2). Part 3 (Simon 2-Stage Phase 2 at the RP2D) will assess clinical benefit in patients with relapsed or refractory malignancies treated with 9-ING-41-based combinations at the RP2D established in Part 2. Safety will be assessed by recording and monitoring adverse events (CTCAE). For solid tumors, response will be defined by response evaluation criteria in solid tumors (RECIST) 1.1 criteria in the evaluable lesion(s). For lymphoma, response will be assessed per the International Working Group Response Criteria. For CNS tumors, response will be followed by the RANO and the MacDonald criteria. The study is opening in 25 sites globally and will accrue approximately 250 patients.
Clinical trial identification
NCT03678883.
Editorial acknowledgement
Legal entity responsible for the study
Actuate Therapeutics Inc.
Funding
Actuate Therapeutics Inc.
Disclosure
B. Carneiro: Research grant / Funding (institution): Actuate Therapeutics Inc; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer. L. Cavalcante: Research grant / Funding (institution): Actuate Therapeutics Inc. P. Munster: Research grant / Funding (institution): Actuate Therapeutics Inc. F. Giles: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Actuate Therapeutics Inc. All other authors have declared no conflicts of interest.
Resources from the same session
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract